Nutriband Inc.
NTRBHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, Nutriband Inc. (NTRB) is listed under Biotechnology. The $72.6M market capitalization puts NTRB squarely in micro-cap range for its industry. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain.
Market Cap
$72.6M
Beta
2.04
P/E (TTM)
—
P/E (Fwd)
-25.96
EPS (TTM)
$-2.56
EPS (Fwd)
$-0.23
ROE
-145.7%
ROA
-78.2%
Cash
$4.0M
Total Debt
$232,714
Free CF
-$1.7M
52W Change
-4.6%
Annual Financials
Cash vs Debt
Where NTRB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NTRB finished 27.03% above its 150-day moving average ($3.70) and 18.69% above its 200-day moving average ($3.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTRB overbought or oversold?
At the September 3, 2026 close, NTRB's RSI(14) was 72.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $4.0M in cash comfortably exceeding the $233K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -145.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $2.1M (2023) to $2.0M (2026).
Nutriband Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, NTRB has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nutriband Inc. and its sector.